BR112023024454A2 - Composto de fórmula geral (1) ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; e; uso do composto ou do isômero - Google Patents

Composto de fórmula geral (1) ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; e; uso do composto ou do isômero

Info

Publication number
BR112023024454A2
BR112023024454A2 BR112023024454A BR112023024454A BR112023024454A2 BR 112023024454 A2 BR112023024454 A2 BR 112023024454A2 BR 112023024454 A BR112023024454 A BR 112023024454A BR 112023024454 A BR112023024454 A BR 112023024454A BR 112023024454 A2 BR112023024454 A2 BR 112023024454A2
Authority
BR
Brazil
Prior art keywords
compound
isomer
general formula
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BR112023024454A
Other languages
English (en)
Portuguese (pt)
Inventor
Houxing Fan
Lihui Qian
Yuli Xie
Original Assignee
Wigen Biomedicine Tech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Tech Shanghai Co Ltd filed Critical Wigen Biomedicine Tech Shanghai Co Ltd
Publication of BR112023024454A2 publication Critical patent/BR112023024454A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112023024454A 2021-06-15 2022-06-15 Composto de fórmula geral (1) ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; e; uso do composto ou do isômero BR112023024454A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110661394 2021-06-15
PCT/CN2022/099018 WO2022262784A1 (zh) 2021-06-15 2022-06-15 Idh突变体抑制剂及其用途

Publications (1)

Publication Number Publication Date
BR112023024454A2 true BR112023024454A2 (pt) 2024-02-06

Family

ID=84526875

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024454A BR112023024454A2 (pt) 2021-06-15 2022-06-15 Composto de fórmula geral (1) ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; e; uso do composto ou do isômero

Country Status (10)

Country Link
US (1) US20240208978A1 (cg-RX-API-DMAC7.html)
EP (1) EP4356914A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884019B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240021774A (cg-RX-API-DMAC7.html)
CN (1) CN117460512A (cg-RX-API-DMAC7.html)
AU (1) AU2022294860A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024454A2 (cg-RX-API-DMAC7.html)
CA (1) CA3217608A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013664A (cg-RX-API-DMAC7.html)
WO (1) WO2022262784A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026035776A1 (en) * 2024-08-05 2026-02-12 Frontier Medicines Corporation Pi3k-alpha binding compounds and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012184205A (ja) * 2011-03-08 2012-09-27 Dainippon Sumitomo Pharma Co Ltd 2−アミノ置換8−オキソジヒドロプリン誘導体
SMT202200255T1 (it) * 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
CA2903979A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MA46064B1 (fr) * 2014-09-19 2020-04-30 Forma Therapeutics Inc Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
US9624175B2 (en) * 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2017019429A1 (en) 2015-07-27 2017-02-02 Eli Lilly And Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
JP6682043B2 (ja) 2016-06-06 2020-04-15 イーライ リリー アンド カンパニー 変異体idh1阻害剤
CN107556366B (zh) * 2016-06-30 2025-02-07 上海海和药物研究开发股份有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
KR102232614B1 (ko) * 2016-07-21 2021-03-29 난징 산홈 팔마세우티칼 컴퍼니 리미티드 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용
JP6793836B2 (ja) * 2016-12-16 2020-12-02 イーライ リリー アンド カンパニー 変異体idh1およびidh2阻害剤としての7−フェニルエチルアミノ−4h−ピリミド[4,5−d][1,3]オキサジン−2−オン化合物
CN110872297B (zh) * 2018-09-04 2023-02-14 上海再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
WO2020141439A1 (en) * 2018-12-31 2020-07-09 Integral Biosciences Private Limited Heterocyclic compounds as mutant idh inhibitors

Also Published As

Publication number Publication date
EP4356914A1 (en) 2024-04-24
CA3217608A1 (en) 2022-12-22
AU2022294860A1 (en) 2024-01-25
MX2023013664A (es) 2024-01-08
KR20240021774A (ko) 2024-02-19
EP4356914A4 (en) 2025-01-08
US20240208978A1 (en) 2024-06-27
JP7884019B2 (ja) 2026-07-02
JP2024524933A (ja) 2024-07-09
WO2022262784A1 (zh) 2022-12-22
CN117460512A (zh) 2024-01-26

Similar Documents

Publication Publication Date Title
BR112023021383A2 (pt) Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmo
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
MX2022006608A (es) Nuevos inhibidores de aurora cinasa y uso de los mismos.
MX2021012756A (es) Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este.
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
BR112021016751B8 (pt) Compostos, composições farmacêuticas e usos dos compostos
PH12020552244A1 (en) Heterocyclic compounds as trk inhibitors
MY209754A (en) Amide derivative and preparation method therefore and use thereof in medicine
BR112021023765A2 (pt) Composto de fórmula (1), um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, inibidor de aurora quinase, composição farmacêutica de combinação e aplicação do composto
MX386103B (es) Inhibidores de mcl-1 y metodos de uso de los mismos.
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
EP4541422A3 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
BR112023015721A2 (pt) Derivados tricíclicos úteis como inibidores de parp7
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
MX2021011144A (es) Derivados de las benzodiazepinas como inhibidores del vsr.
ZA202400988B (en) Aak1 inhibitor and use thereof
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
BRPI0809542A8 (pt) Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos
MX2021003662A (es) Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo.
MX2019008331A (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
BR112022002107A2 (pt) Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo
MX389786B (es) Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer.
MX2019012967A (es) Cristal de base libre de derivados benzofurano y metodo de preparacion.